Filing Flows › Neurocrine Biosciences (NBIX) › Q3 2026 › vs Q2 2026
Neurocrine Biosciences (NBIX) Q3 2026 vs Q2 2026 (quarter over quarter)
Neurocrine Biosciences's revenue rose $164M (+17%) from $959M in Q2 2026 to $1.1B in Q3 2026. Operating margin 29.5% against 15.8% (+13.7 pts).
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 29.5% | 15.8% | +13.7 pts |
| Net margin | 18.4% | 15.1% | +3.3 pts |
| Free cash flow margin | 34.2% | 13.4% | +20.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.1B | $959M | $164M | +17% |
| Operating profit | $331M | $152M | $180M | +119% |
| Costs & expenses | $791M | $808M | −$16.1M | -2% |
| Pre-tax earnings | $284M | $162M | $122M | +75% |
| Other expense, net | $47.6M | −$10.7M | $58.3M | — |
| Cost of revenue | $26.6M | $23.2M | $3.4M | +15% |
| Research & development | $352M | $327M | $25.1M | +8% |
| SG&A | $366M | $440M | −$73.4M | -17% |
| Other operating costs | $46.7M | $17.9M | $28.8M | +161% |
| Net earnings | $206M | $144M | $62.1M | +43% |
| Income tax | $77.2M | $17.8M | $59.4M | +334% |
| Depreciation & amortization | $44.0M | $24.8M | $19.2M | +77% |
| Share-based compensation | $54.3M | $65.0M | −$10.7M | -16% |
| Working capital & other | $90.4M | −$97.8M | $188M | — |
| Operating cash flow | $395M | $136M | $259M | +190% |
| Free cash flow (OCF − capex) | $384M | $129M | $255M | +198% |
| Capital expenditures | $11.6M | $7.8M | $3.8M | +49% |
Questions
How much did Neurocrine Biosciences's revenue grow quarter over quarter in Q3 2026?
Neurocrine Biosciences's revenue rose $164M (+17%) from $959M in Q2 2026 to $1.1B in Q3 2026. Operating margin 29.5% against 15.8% (+13.7 pts).